Item 1.02 Termination of a Material Definitive Agreement

On August 23, 2022, Elite Pharmaceuticals Inc. ("Elite") received notification from Lannett Company, Inc. ("Lannett") that they are terminating the License, Supply and Distribution Agreement for Mixed Salts for Single Entity Amphetamine Tablets and Mixed Salts for Single Entity Amphetamine Extended-Release Capsules ("Amphetamines Agreement") effective as of March 31, 2023. All marketing rights will return at that time to Elite and its partner, Mikah Pharma LLC.

In anticipation of the return of the marketing rights, Elite will either develop its own sales, marketing, and distribution system to sell products under an Elite label or choose a replacement sales and marketing partner. Elite will move forward with the most financially attractive alternative.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document).

© Edgar Online, source Glimpses